AMP-activated protein kinase: A key regulator of energy balance with many roles in human disease

Journal of Internal Medicine

Volumn 276, Issue 6, 2014, Pages 543-559

  Hardie, D Grahame ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Biochemistry; Cancer; Cell biology; Metformin; Type 2 diabetes mellitus; Wolff Parkinson White syndrome

Indexed keywords

6 PHOSPHOFRUCTO 2 KINASE; 6,7 DIHYDRO 4 HYDROXY 3 (2' HYDROXY 1,1' BIPHENYL 4 YL) 6 OXOTHIENO[2,3 B]PYRIDINE 5 CARBONITRILE; ACETYL COENZYME A CARBOXYLASE; ADENOSINE DIPHOSPHATE; ADENOSINE PHOSPHATE; ADENYLATE KINASE; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE; CARNITINE PALMITOYLTRANSFERASE I; GLUCOSE; GLUCOSE TRANSPORTER 4; GLYCOGEN; GLYCOGEN SYNTHASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE ACTIVATOR; MALONYL COENZYME A; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PHENFORMIN; PHOSPHOLIPID; PROTEIN 14 3 3; PROTEIN KINASE LKB1; PROTEINASE ACTIVATED RECEPTOR 1; RIBOSOME RNA; SALICYLIC ACID; SIRTUIN 1; STAUROSPORINE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TRIACYLGLYCEROL; TUBERIN; UNINDEXED DRUG; ADENINE NUCLEOTIDE; CALCIUM CHANNEL;

AEROBIC METABOLISM; AMINO ACID SUBSTITUTION; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; AUTOPHAGY; CARBOXY TERMINAL SEQUENCE; CARCINOGENESIS; CELL CYCLE ARREST; CELL GROWTH; CHOLESTEROL SYNTHESIS; CRYSTAL STRUCTURE; ENERGY BALANCE; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; ENZYME STRUCTURE; ENZYME SUBUNIT; FATTY ACID OXIDATION; FATTY ACID SYNTHESIS; FATTY ACID TRANSPORT; GENE MUTATION; GLUCOSE TRANSPORT; GLYCOGEN ANALYSIS; GLYCOGEN STORAGE DISEASE; GLYCOGEN SYNTHESIS; GLYCOLYSIS; HEART ARRHYTHMIA; HEART DISEASE; HEART MUSCLE CELL; HEPATITIS C VIRUS; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; INFLAMMATION; INFLAMMATORY DISEASE; INSULIN RESISTANCE; METABOLIC STRESS; MITOCHONDRIAL RESPIRATION; MITOPHAGY; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PEUTZ JEGHERS SYNDROME; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN SYNTHESIS; REGULATORY MECHANISM; REVIEW; RNA SYNTHESIS; TUMOR SUPPRESSOR GENE; VIRUS INFECTION; VIRUS REPLICATION; WOLFF PARKINSON WHITE SYNDROME; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; ENERGY METABOLISM; ENZYMOLOGY; GENETICS; METABOLISM; MUTATION;

ADENINE NUCLEOTIDES; AMP-ACTIVATED PROTEIN KINASES; CALCIUM CHANNELS; CARDIOMYOPATHY, HYPERTROPHIC; DIABETES MELLITUS, TYPE 2; ENERGY METABOLISM; HUMANS; INFLAMMATION; MOLECULAR STRUCTURE; MUTATION; NEOPLASMS; VIRUS DISEASES;

EID: 84907994949     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/joim.12268     Document Type: Review

References (118)

1. Carlson CA, Kim KH. Regulation of hepatic acetyl coenzyme A carboxylase by phosphorylation and dephosphorylation. J Biol Chem 1973; 248: 378-80.
2. Beg ZH, Allmann DW, Gibson DM. Modulation of 3-hydroxy-3-methylglutaryl coenzyme: a reductase activity with cAMP and with protein fractions of rat liver cytosol. Biochem Biophys Res Commun 1973; 54: 1362-9.
3. Carling D, Zammit VA, Hardie DG. A common bicyclic protein kinase cascade inactivates the regulatory enzymes of fatty acid and cholesterol biosynthesis. FEBS Lett 1987; 223: 217-22.
4. Hardie DG, Carling D, Sim ATR. The AMP-activated protein kinase - a multisubstrate regulator of lipid metabolism. Trends Biochem Sci 1989; 14: 20-3.
5. Hardie DG, Ross FA, Hawley SA. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol 2012; 13: 251-62.
6. Hawley SA, Davison M, Woods A et al. Characterization of the AMP-activated protein kinase kinase from rat liver, and identification of threonine-172 as the major site at which it phosphorylates and activates AMP-activated protein kinase. J Biol Chem 1996; 271: 27879-87.
7. Davies SP, Sim AT, Hardie DG. Location and function of three sites phosphorylated on rat acetyl-CoA carboxylase by the AMP-activated protein kinase. Eur J Biochem 1990; 187: 183-90.
8. Gowans GJ, Hawley SA, Ross FA, Hardie DG. AMP is a true physiological regulator of AMP-activated protein kinase by both allosteric activation and enhancing net phosphorylation. Cell Metab 2013; 18: 556-66.
9. Hawley SA, Boudeau J, Reid JL et al. Complexes between the LKB1 tumor suppressor, STRADα/β and MO25α/β are upstream kinases in the AMP-activated protein kinase cascade. J Biol 2003; 2: 28.
10. Woods A, Johnstone SR, Dickerson K et al. LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. Curr Biol 2003; 13: 2004-8.
11. Shaw RJ, Kosmatka M, Bardeesy N et al. The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc Natl Acad Sci U S A 2004; 101: 3329-35.
12. Alessi DR, Sakamoto K, Bayascas JR. Lkb1-dependent signaling pathways. Annu Rev Biochem 2006; 75: 137-63.
13. Xiao B, Sanders MJ, Underwood E et al. Structure of mammalian AMPK and its regulation by ADP. Nature 2011; 472: 230-3.
14. Hawley SA, Pan DA, Mustard KJ et al. Calmodulin-dependent protein kinase kinase-beta is an alternative upstream kinase for AMP-activated protein kinase. Cell Metab 2005; 2: 9-19.
15. 2+/calmodulin-dependent protein kinase kinase-beta acts upstream of AMP-activated protein kinase in mammalian cells. Cell Metab 2005; 2: 21-33.
16. 2+/calmoldulin-dependent protein kinase kinases are AMP-activated protein kinase kinases. J Biol Chem 2005; 280: 29060-6.
17. Oakhill JS, Steel R, Chen ZP et al. AMPK is a direct adenylate charge-regulated protein kinase. Science 2011; 332: 1433-5.
18. 2+ and AMP. Biochem J 2010; 426: 109-18.
19. 2+ in T lymphocytes. J Exp Med 2006; 203: 1665-70.
20. 2+/calmodulin-dependent protein kinase kinase beta. Mol Cell Biol 2006; 26: 5933-45.
21. Yang Y, Atasoy D, Su HH, Sternson SM. Hunger states switch a flip-flop memory circuit via a synaptic AMPK-dependent positive feedback loop. Cell 2011; 146: 992-1003.
22. Xiao B, Sanders MJ, Carmena D et al. Structural basis of AMPK regulation by small molecule activators. Nat Commun 2013; 4: 3017.
23. Scott JW, Norman DG, Hawley SA, Kontogiannis L, Hardie DG. Protein kinase substrate recognition studied using the recombinant catalytic domain of AMP-activated protein kinase and a model substrate. J Mol Biol 2002; 317: 309-23.
24. Chen L, Jiao ZH, Zheng LS et al. Structural insight into the autoinhibition mechanism of AMP-activated protein kinase. Nature 2009; 459: 1146-9.
25. Hudson ER, Pan DA, James J et al. A novel domain in AMP-activated protein kinase causes glycogen storage bodies similar to those seen in hereditary cardiac arrhythmias. Curr Biol 2003; 13: 861-6.
26. Polekhina G, Gupta A, van Denderen BJ et al. Structural basis for glycogen recognition by AMP-activated protein kinase. Structure 2005; 13: 1453-62.
27. Scott JW, Hawley SA, Green KA et al. CBS domains form energy-sensing modules whose binding of adenosine ligands is disrupted by disease mutations. J Clin Invest 2004; 113: 274-84.
28. Chen L, Xin FJ, Wang J et al. Conserved regulatory elements in AMPK. Nature 2013; 498: E8-10.
29. Imamura K, Ogura T, Kishimoto A, Kaminishi M, Esumi H. Cell cycle regulation via p53 phosphorylation by a 5′-AMP activated protein kinase activator, 5-aminoimidazole- 4-carboxamide-1-beta-d- ribofuranoside, in a human hepatocellular carcinoma cell line. Biochem Biophys Res Commun 2001; 287: 562-7.
30. He G, Zhang YW, Lee JH et al. AMP-activated protein kinase induces p53 by phosphorylating MDMX and inhibiting its activity. Mol Cell Biol 2014; 34: 148-57.
31. Chen S, Wasserman DH, MacKintosh C, Sakamoto K. Mice with AS160/TBC1D4-Thr649Ala knockin mutation are glucose intolerant with reduced insulin sensitivity and altered GLUT4 trafficking. Cell Metab 2011; 13: 68-79.
32. Taylor EB, An D, Kramer HF et al. Discovery of TBC1D1 as an Insulin-, AICAR-, and Contraction-stimulated Signaling Nexus in Mouse Skeletal Muscle. J Biol Chem 2008; 283: 9787-96.
33. Chen S, Murphy J, Toth R, Campbell DG, Morrice NA, Mackintosh C. Complementary regulation of TBC1D1 and AS160 by growth factors, insulin and AMPK activators. Biochem J 2008; 409: 449-59.
34. Pehmoller C, Treebak JT, Birk JB et al. Genetic disruption of AMPK signaling abolishes both contraction- and insulin-stimulated TBC1D1 phosphorylation and 14-3-3 binding in mouse skeletal muscle. Am J Physiol Endocrinol Metab 2009; 297: E665-75.
35. Hatakeyama H, Kanzaki M. Regulatory mode shift of Tbc1d1 is required for acquisition of insulin-responsive GLUT4-trafficking activity. Mol Biol Cell 2013; 24: 809-17.
36. Corton JM, Gillespie JG, Hawley SA, Hardie DG. 5-Aminoimidazole-4-carboxamide ribonucleoside: a specific method for activating AMP-activated protein kinase in intact cells? Eur J Biochem 1995; 229: 558-65.
37. Merrill GM, Kurth E, Hardie DG, Winder WW. AICAR decreases malonyl-CoA and increases fatty acid oxidation in skeletal muscle of the rat. Am J Physiol 1997; 273: E1107-12.
38. Jager S, Handschin C, St-Pierre J, Spiegelman BM. AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1{alpha}. Proc Natl Acad Sci U S A 2007; 104: 12017-22.
39. Canto C, Jiang LQ, Deshmukh AS et al. Interdependence of AMPK and SIRT1 for metabolic adaptation to fasting and exercise in skeletal muscle. Cell Metab 2010; 11: 213-9.
40. Li Y, Xu S, Mihaylova MM et al. AMPK phosphorylates and Inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice. Cell Metab 2011; 13: 376-88.
41. Muoio DM, Seefeld K, Witters LA, Coleman RA. AMP-activated kinase reciprocally regulates triacylglycerol synthesis and fatty acid oxidation in liver and muscle: evidence that sn-glycerol- 3-phosphate acyltransferase is a novel target. Biochem J 1999; 338: 783-91.
42. Inoki K, Zhu T, Guan KL. TSC2 mediates cellular energy response to control cell growth and survival. Cell 2003; 115: 577-90.
43. Gwinn DM, Shackelford DB, Egan DF et al. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell 2008; 30: 214-26.
44. Hoppe S, Bierhoff H, Cado I et al. AMP-activated protein kinase adapts rRNA synthesis to cellular energy supply. Proc Natl Acad Sci U S A 2009; 106: 17781-6.
45. Arad M, Seidman CE, Seidman JG. AMP-activated protein kinase in the heart: role during health and disease. Circ Res 2007; 100: 474-88.
46. Gollob MH, Seger JJ, Gollob TN et al. Novel PRKAG2 mutation responsible for the genetic syndrome of ventricular preexcitation and conduction system disease with childhood onset and absence of cardiac hypertrophy. Circulation 2001; 104: 3030-3.
47. Akman HO, Sampayo JN, Ross FA et al. Fatal infantile cardiac glycogenosis with phosphorylase kinase deficiency and a mutation in the gamma-2 subunit of AMP-activated protein kinase. Pediatr Res 2007; 62: 499-504.
48. Burwinkel B, Scott JW, Buhrer C et al. Fatal congenital heart glycogenosis caused by a recurrent activating R531Q mutation in the g2 subunit of AMP-activated protein kinase (PRKAG2), not by phosphorylase kinase deficiency. Am J Hum Genet 2005; 76: 1034-49.
49. Xiao B, Heath R, Saiu P et al. Structural basis for AMP binding to mammalian AMP-activated protein kinase. Nature 2007; 449: 496-500.
50. Daniel TD, Carling D. Functional analysis of mutations in the γ2 subunit of AMP-activated protein kinase associated with cardiac hypertrophy and Wolff-Parkinson-White syndrome. J Biol Chem 2002; 277: 51017-24.
51. Hawley SA, Ross FA, Chevtzoff C et al. Use of cells expressing gamma subunit variants to identify diverse mechanisms of AMPK activation. Cell Metab 2010; 11: 554-65.
52. Arad M, Benson DW, Perez-Atayde AR et al. Constitutively active AMP kinase mutations cause glycogen storage disease mimicking hypertrophic cardiomyopathy. J Clin Invest 2002; 109: 357-62.
53. Arad M, Moskowitz IP, Patel VV et al. Transgenic mice overexpressing mutant PRKAG2 define the cause of Wolff-Parkinson-White syndrome in glycogen storage cardiomyopathy. Circulation 2003; 107: 2850-6.
54. Sidhu JS, Rajawat YS, Rami TG et al. Transgenic mouse model of ventricular preexcitation and atrioventricular reentrant tachycardia induced by an AMP-activated protein kinase loss-of-function mutation responsible for Wolff-Parkinson-White Syndrome. Circulation 2005; 111: 21-29.
55. Davies JK, Wells DJ, Liu K et al. Characterization of the role of gamma2 R531G mutation in AMP-activated protein kinase in cardiac hypertrophy and Wolff-Parkinson-White syndrome. Am J Physiol Heart Circ Physiol 2006; 290: H1942-51.
56. Luptak I, Shen M, He H et al. Aberrant activation of AMP-activated protein kinase remodels metabolic network in favor of cardiac glycogen storage. J Clin Invest 2007; 117: 1432-9.
57. Kim M, Hunter RW, Garcia-Menendez L et al. Mutation in the gamma-2 subunit of AMPK stimulates cardiomyocyte proliferation and hypertrophy independent of glycogen storage. Circ Res 2014; 114: 966-75.
58. Cheung PCF, Salt IP, Davies SP, Hardie DG, Carling D. Characterization of AMP-activated protein kinase γ subunit isoforms and their role in AMP binding. Biochem J 2000; 346: 659-69.
59. Milan D, Jeon JT, Looft C et al. A mutation in PRKAG3 associated with excess glycogen content in pig skeletal muscle. Science 2000; 288: 1248-51.
60. Holmes BF, Kurth-Kraczek EJ, Winder WW. Chronic activation of 5′-AMP-activated protein kinase increases GLUT-4, hexokinase, and glycogen in muscle. J Appl Physiol 1999; 87: 1990-5.
61. Narkar VA, Downes M, Yu RT et al. AMPK and PPARdelta agonists are exercise mimetics. Cell 2008; 134: 405-15.
62. Samuel VT, Petersen KF, Shulman GI. Lipid-induced insulin resistance: unravelling the mechanism. Lancet 2010; 375: 2267-77.
63. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest 2006; 116: 1793-801.
64. Fu S, Watkins SM, Hotamisligil GS. The role of endoplasmic reticulum in hepatic lipid homeostasis and stress signaling. Cell Metab 2012; 15: 623-34.
65. O'Neill HM, Maarbjerg SJ, Crane JD et al. AMP-activated protein kinase (AMPK) {beta}1{beta}2 muscle null mice reveal an essential role for AMPK in maintaining mitochondrial content and glucose uptake during exercise. Proc Natl Acad Sci U S A 2011; 108: 16092-7.
66. Lochhead PA, Salt IP, Walker KS, Hardie DG, Sutherland C. 5-aminoimidazole-4-carboxamide riboside mimics the effects of insulin on the expression of the 2 key gluconeogenic genes PEPCK and glucose-6-phosphatase. Diabetes 2000; 49: 896-903.
67. Koo SH, Flechner L, Qi L et al. The CREB coactivator TORC2 is a key regulator of fasting glucose metabolism. Nature 2005; 437: 1109-14.
68. Bergeron R, Previs SF, Cline GW et al. Effect of 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside infusion on in vivo glucose and lipid metabolism in lean and obese Zucker rats. Diabetes 2001; 50: 1076-82.
69. Buhl ES, Jessen N, Pold R et al. Long-term AICAR administration reduces metabolic disturbances and lowers blood pressure in rats displaying features of the insulin resistance syndrome. Diabetes 2002; 51: 2199-206.
70. Song XM, Fiedler M, Galuska D et al. 5-Aminoimidazole-4-caboxamide ribonucleoside treatment improves glucose homeostasis in insulin-resistant diabetic (ob/ob) mice. Diabetologia 2002; 45: 56-65.
71. Iglesias MA, Ye JM, Frangioudakis G et al. AICAR administration causes an apparent enhancement of muscle and liver insulin action in insulin-resistant high-fat-fed rats. Diabetes 2002; 51: 2886-94.
72. Zhou G, Myers R, Li Y et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001; 108: 1167-74.
73. Cool B, Zinker B, Chiou W et al. Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome. Cell Metab 2006; 3: 403-16.
74. Lee YS, Kim WS, Kim KH et al. Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes 2006; 55: 2256-64.
75. Foretz M, Hebrard S, Leclerc J et al. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J Clin Invest 2010; 120: 2355-69.
76. Vincent MF, Marangos PJ, Gruber HE, Van den Berghe G. Inhibition by AICA riboside of gluconeogenesis in isolated rat hepatocytes. Diabetes 1991; 40: 1259-66.
77. Miller RA, Chu Q, Xie J, Foretz M, Viollet B, Birnbaum MJ. Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP. Nature 2013; 494: 256-60.
78. Fullerton MD, Galic S, Marcinko K et al. Single phosphorylation sites in ACC1 and ACC2 regulate lipid homeostasis and the insulin-sensitizing effects of metformin. Nat Med 2013; 19: 1649-54.
79. Miyoshi H, Nakau M, Ishikawa TO, Seldin MF, Oshima M, Taketo MM. Gastrointestinal hamartomatous polyposis in LKB1 heterozygous knockout mice. Cancer Res 2002; 62: 2261-6.
80. Nakau M, Miyoshi H, Seldin MF, Imamura M, Oshima M, Taketo MM. Hepatocellular carcinoma caused by loss of heterozygosity in LKB1 gene knockout mice. Cancer Res 2002; 62: 4549-53.
81. Lizcano JM, Göransson O, Toth R et al. LKB1 is a master kinase that activates 13 protein kinases of the AMPK subfamily, including the MARK/PAR-1 kinases. EMBO J 2004; 23: 833-43.
82. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009; 324: 1029-33.
83. Huang X, Wullschleger S, Shpiro N et al. Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice. Biochem J 2008; 412: 211-21.
84. Faubert B, Boily G, Izreig S et al. AMPK Is a negative regulator of the Warburg effect and suppresses tumor growth In vivo. Cell Metab 2012; 17: 113-24.
85. Thomas GV, Tran C, Mellinghoff IK et al. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 2006; 12: 122-7.
86. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005; 330: 1304-5.
87. Noto H, Goto A, Tsujimoto T, Noda M. Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PLoS ONE 2012; 7: e33411.
88. Algire C, Amrein L, Bazile M, David S, Zakikhani M, Pollak M. Diet and tumor LKB1 expression interact to determine sensitivity to anti-neoplastic effects of metformin in vivo. Oncogene 2011; 30: 1174-82.
89. Shackelford DB, Abt E, Gerken L et al. LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin. Cancer Cell 2013; 23: 143-58.
90. Sanchez-Cespedes M, Parrella P, Esteller M et al. Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung. Cancer Res 2002; 62: 3659-62.
91. Ji H, Ramsey MR, Hayes DN et al. LKB1 modulates lung cancer differentiation and metastasis. Nature 2007; 448: 807-10.
92. Wingo SN, Gallardo TD, Akbay EA et al. Somatic LKB1 mutations promote cervical cancer progression. PLoS ONE 2009; 4: e5137.
93. Liu W, Monahan KB, Pfefferle AD et al. LKB1/STK11 inactivation leads to expansion of a prometastatic tumor subpopulation in melanoma. Cancer Cell 2012; 21: 751-64.
94. Lee CW, Wong LL, Tse EY et al. AMPK promotes p53 acetylation via phosphorylation and inactivation of SIRT1 in liver cancer cells. Cancer Res 2012; 72: 4394-404.
95. Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a theme. Oncogene 2008; 27: 5497-510.
96. Horman S, Vertommen D, Heath R et al. Insulin antagonizes ischemia-induced Thr172 phosphorylation of AMP-activated protein kinase alpha-subunits in heart via hierarchical phosphorylation of Ser485/491. J Biol Chem 2006; 281: 5335-40.
97. Hawley SA, Ross FA, Gowans GJ, Tibarewal P, Leslie NR, Hardie DG. Phosphorylation by Akt within the ST loop of AMPK-α1 down-regulates its activation in tumour cells. Biochem J 2014; 459: 275-87.
98. Steinberg GR, Dandapani M, Hardie DG. AMPK: mediating the metabolic effects of salicylate-based drugs? Trends Endocrinol Metab 2013; 24: 481-7.
99. Krawczyk CM, Holowka T, Sun J et al. Toll-like receptor-induced changes in glycolytic metabolism regulate dendritic cell activation. Blood 2010; 115: 4742-9.
100. Sag D, Carling D, Stout RD, Suttles J. Adenosine 5′-monophosphate-activated protein kinase promotes macrophage polarization to an anti-inflammatory functional phenotype. J Immunol 2008; 181: 8633-41.
101. Yang Z, Kahn BB, Shi H, Xue BZ. Macrophage {alpha}1-AMP-activated protein kinase ({alpha}1AMPK) antagonizes fatty acid-induced inflammation through SIRT1. J Biol Chem 2010; 285: 19051-9.
102. Galic S, Fullerton MD, Schertzer JD et al. Hematopoietic AMPK beta1 reduces mouse adipose tissue macrophage inflammation and insulin resistance in obesity. J Clin Invest 2011; 121: 4903-15.
103. Mounier R, Theret M, Arnold L et al. AMPKalpha1 regulates macrophage skewing at the time of resolution of inflammation during skeletal muscle regeneration. Cell Metab 2013; 18: 251-64.
104. Hawley SA, Fullerton MD, Ross FA et al. The ancient drug salicylate directly activates AMP-activated protein kinase. Science 2012; 336: 918-22.
105. Amann R, Peskar BA. Anti-inflammatory effects of aspirin and sodium salicylate. Eur J Pharmacol 2002; 447: 1-9.
106. April P, Abeles M, Baraf H et al. Does the acetyl group of aspirin contribute to the antiinflammatory efficacy of salicylic acid in the treatment of rheumatoid arthritis? Semin Arthritis Rheum 1990; 19: 20-8.
107. Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 2011; 377: 31-41.
108. Mankouri J, Tedbury PR, Gretton S et al. Enhanced hepatitis C virus genome replication and lipid accumulation mediated by inhibition of AMP-activated protein kinase. Proc Natl Acad Sci U S A 2010; 107: 11549-54.
109. Street A, Macdonald A, Crowder K, Harris M. The Hepatitis C virus NS5A protein activates a phosphoinositide 3-kinase-dependent survival signaling cascade. J Biol Chem 2004; 279: 12232-41.
110. Mankouri J, Harris M. Viruses and the fuel sensor: the emerging link between AMPK and virus replication. Rev Med Virol 2011; 21: 205-12.
111. Wang DS, Jonker JW, Kato Y, Kusuhara H, Schinkel AH, Sugiyama Y. Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin. J Pharmacol Exp Ther 2002; 302: 510-5.
112. Bailey CJ, Wilcock C, Day C. Effect of metformin on glucose metabolism in the splanchnic bed. Br J Pharmacol 1992; 105: 1009-13.
113. Wang DS, Kusuhara H, Kato Y, Jonker JW, Schinkel AH, Sugiyama Y. Involvement of organic cation transporter 1 in the lactic acidosis caused by metformin. Mol Pharmacol 2003; 63: 844-8.
114. Cuthbertson DJ, Babraj JA, Mustard KJ et al. 5-aminoimidazole-4-carboxamide 1-beta-D-ribofuranoside acutely stimulates skeletal muscle 2-deoxyglucose uptake in healthy men. Diabetes 2007; 56: 2078-84.
115. Wolf CM, Arad M, Ahmad F et al. Reversibility of PRKAG2 glycogen-storage cardiomyopathy and electrophysiological manifestations. Circulation 2008; 117: 144-54.
116. Yu PB, Hong CC, Sachidanandan C et al. Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism. Nat Chem Biol 2008; 4: 33-41.
117. Bain J, Plater L, Elliott M et al. The selectivity of protein kinase inhibitors: a further update. Biochem J 2007; 408: 297-315.
118. Abu-Elheiga L, Matzuk MM, Abo-Hashema KA, Wakil SJ. Continuous fatty acid oxidation and reduced fat storage in mice lacking acetyl-CoA carboxylase 2. Science 2001; 291: 2613-6.